Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03563001
Other study ID # 2016-HXNK-002
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date June 20, 2018
Est. completion date September 2018

Study information

Verified date May 2018
Source Zhujiang Hospital
Contact Huapeng Yu
Phone +86 020-61643888
Email 359606545@qq.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to research the differences of small airways function between subjects with diagnosis of chronic obstructive pulmonary disease(COPD) and asthma-COPD overlap(ACO).The assessment of quality of life is also carried out through questionnaires.


Description:

This is a randomized,open-label study to research the differences of small airways function between simple chronic obstructive pulmonary disease(COPD) and asthma-COPD overlap(ACO).Assessment of small airways is conducted at baseline,including forced expired volume in one second(FEV1),forced vital capacity(FVC),peak expiratory flow(PEF),maximum expiratory flow rate at 75% of vital capacity(MEF75),maximum expiratory flow rate at 50% of vital capacity(MEF50),maximum expiratory flow rate at 25% of vital capacity(MEF25),impulse oscillometry,diffusion function,residual volume(RV) and total lung capacity(TLC).Budesonide(160ug) and formoterol(4.5ug) bid will be given to both groups(chronic obstructive pulmonary disease and asthma-COPD overlap) for 3 months.Quality of life is assessed through questionnaires including modified Medical Research Council dyspnoea scale(mMRC),St George's Respiratory Questionnaire(SGRQ) and chronic obstructive pulmonary disease assessment test(CAT).All of the patients will have a follow-up visit after 3 months` treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date September 2018
Est. primary completion date September 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Male or female patients 18 to 80 years-old.

- A diagnosis of chronic obstructive pulmonary disease according to the Global Initiative for Chronic Obstructive Disease(GOLD 2018) guidelines are recruited to the chronic obstructive pulmonary disease group.A diagnosis of asthma-chronic obstructive pulmonary disease overlap according to Global Initiative for Chronic Obstructive Disease(GOLD 2018),Global Initiative for Asthma(GINA 2018) and Spanish COPD Guidelines(GesEPOC 2017) are recruited to the asthma-chronic obstructive pulmonary disease overlap group.

- Willing and able to provide written informed consent.

- Willing and able to attend all study visits and adhere to all study assessments and procedures.

Exclusion Criteria:

- Severe comorbidities including unstable cardiac or pulmonary disease or any other medical conditions including unstable ischemic heart disease,unstable cardiac arrhythmia or heart failure,life threatening arrhythmias,etc.

- Recent history of chronic obstructive pulmonary disease exacerbation requiring hospitalization or need for increased treatments for chronic obstructive pulmonary disease within 6 weeks.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Budesonide(160ug) and Formoterol(4.5ug) bid
For both groups of subjects,small airways function of is assessed at baseline.And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with the same examinations after 3 months` treatment.

Locations

Country Name City State
China Zhujiang Hospital of Southern Medical University Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Zhujiang Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Differences of maximum expiratory flow rate at 75% of vital capacity(MEF75) between chronic obstructive pulmonary disease and asthma-chronic obstructive pulmonary disease overlap Maximum expiratory flow rate at 75% of vital capacity(MEF75) is measured according to internationally accepted standards in both groups by Jaeger MasterScreen Pulmonary Function Test System. 3 months
Secondary Differences of maximum expiratory flow rate at 50% of vital capacity(MEF50) between two groups Maximum expiratory flow rate at 50% of vital capacity(MEF50) is measured according to internationally accepted standards in both groups by Jaeger MasterScreen Pulmonary Function Test System. 3 months
Secondary Differences of maximum expiratory flow rate at 25% of vital capacity(MEF25) between two groups Maximum expiratory flow rate at 25% of vital capacity(MEF25) is measured according to internationally accepted standards in both groups by Jaeger MasterScreen Pulmonary Function Test System. 3 months
Secondary Differences of impulse oscillometry parameters between two groups Impulse oscillometry parameters are measured according to internationally accepted standards in both groups by Jaeger MasterScreen Pulmonary Function Test System. 3 months
Secondary Differences of diffusion function between two groups Diffusion function is measured according to internationally accepted standards in both groups by Jaeger MasterScreen Pulmonary Function Test System. 3 months
Secondary Differences of residual volume(RV) between two groups Residual volume(RV) is measured according to internationally accepted standards in both groups by Jaeger MasterScreen Pulmonary Function Test System. 3 months
Secondary Differences of total lung capacity(TLC) between two groups Total lung capacity(TLC) is measured according to internationally accepted standards in both groups by Jaeger MasterScreen Pulmonary Function Test System. 3 months
Secondary Changes of maximum expiratory flow rate at 75% of vital capacity(MEF75) after 3 months` treatment compared with baseline in both groups At baseline,maximum expiratory flow rate at 75% of vital capacity(MEF75) is performed in each subject.After 3 months`s treatment of budesonide and formoterol,the test will be performed again. Change from baseline to 3 months
Secondary Changes of maximum expiratory flow rate at 50% of vital capacity(MEF50) after 3 months` treatment compared with baseline in both groups At baseline,maximum expiratory flow rate at 50% of vital capacity(MEF50) is performed in each subject.After 3 months`s treatment of budesonide and formoterol,the test will be performed again. Change from baseline to 3 months
Secondary Changes of maximum expiratory flow rate at 25% of vital capacity(MEF25) after 3 months` treatment compared with baseline in both groups At baseline,maximum expiratory flow rate at 25% of vital capacity(MEF25) is performed in each subject.After 3 months`s treatment of budesonide and formoterol,the test will be performed again. Change from baseline to 3 months
Secondary Changes of impulse oscillometry parameters(IOS) after 3 months` treatment compared with baseline in both groups At baseline,impulse oscillometry is performed in each subject.After 3 months`s treatment of budesonide and formoterol,the test will be performed again. Change from baseline to 3 months
Secondary Changes of diffusion function after 3 months` treatment compared with baseline in both groups At baseline,diffusion function is performed in each subject.After 3 months`s treatment of budesonide and formoterol,the test will be performed again. Change from baseline to 3 months
Secondary Changes of total lung capacity(TLC) after 3 months` treatment compared with baseline in both groups At baseline,total lung capacity(TLC) is performed in each subject.After 3 months`s treatment of budesonide and formoterol,the test will be performed again. Change from baseline to 3 months
Secondary Changes of residual volume(RV) after 3 months` treatment compared with baseline in both groups At baseline,residual volume(RV) is performed in each subject.After 3 months`s treatment of budesonide and formoterol,the test will be performed again. Change from baseline to 3 months
Secondary Change of St George's Respiratory Questionnaire(SGRQ) scores after 3 months` treatment compared with baseline The SGRQ questionnaire is developed to measure the quality of life in patients with chronic airway diseases.Scores range from 0 to 100,higher scores indicates worse respiratory condition.The St George's Respiratory Questionnaire is performed in both groups at baseline.After 3 months`s treatment of budesonide and formoterol,the scores will be measured again. Change from baseline to 3 months
Secondary Change of modified Medical Research Council dyspnoea scale(mMRC) scores after 3 months` treatment compared with baseline The mMRC scale is used to assess the degree of breathlessness.The scores range from 0 to 4,higher scores indicates more serious respiratory condition.The mMRC is performed in both groups at baseline.After 3 months`s treatment of budesonide and formoterol,the scores will be measured again. Change from baseline to 3 months
Secondary Change of chronic obstructive pulmonary disease assessment test(CAT) after 3 months` treatment compared with baseline The CAT test is used to assess the impact of COPD on patients` daily life.The scores range from 0 to 40,higher scores indicates worse respiratory condition.The CAT test is performed in both groups at baseline.After 3 months`s treatment of budesonide and formoterol,the test will be performed again. Change from baseline to 3 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05559255 - Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI N/A
Completed NCT06238557 - Prospective Evaluation of Psychological Consequences and Impact on Long-term Quality of Life
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT05472935 - Asynchronous Mindfulness Based Stress Reduction to Reduce Burnout in Licensed Clinical Social Workers N/A
Recruiting NCT04444544 - Quality of Life and High-Risk Abdominal Cancer Surgery
Completed NCT04281953 - Impact on Quality of Life of Long-term Ototoxicity in Cancer Survivors
Recruiting NCT05546931 - Mobile Health Program for Rural Hypertension N/A
Active, not recruiting NCT04746664 - Effects of Nutrition Counselling on Old Age People's Nutritional Status and Quality of Life in Bahir Dar City, North West Ethiopia N/A
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Recruiting NCT04142827 - The Effect of Long Term Therapy With High Flow Humidification Compared to Usual Care in Patients With Bronchiectasis (BX) N/A
Active, not recruiting NCT05903638 - A Pilot RCT: the Impact of a Virtual MBSR Course on Women With Primary Infertility N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Completed NCT06216015 - Exercise Training and Kidney Transplantation N/A
Completed NCT03813420 - Sleep Quality of Physiotherapy Students Quality of Life and Physical Activity Level N/A
Recruiting NCT05550545 - Infant RSV Infections and Health-related Quality of Life of Families
Completed NCT05346588 - THRIVE Feasibility Trial Phase 3
Recruiting NCT05233020 - Robotic Versus Hybrid Assisted Ventral Hernia Repair N/A
Terminated NCT03304184 - The Role of Biodentine in Class V Dental Lesions on Oral Health Related Quality of Life Phase 3
Completed NCT05063305 - Probiotics, Immunity, Stress, and QofL N/A
Recruiting NCT05380856 - Sacral Neuromodulation for Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction N/A